文献速递临床试验与 GCP

肥胖患者麻醉诱导时甲苯磺酸瑞马唑仑不同体重标量比较:一项前瞻性对照试验的研究方案

Comparison of different weight-based scalars of remimazolam tosylate for anesthesia induction in obese patients: study protocol for a prospective, controlled trial.
PubMed 文献 · Trials · 2023-11-10

本研究为前瞻性、单中心、双盲、对照临床试验,旨在比较肥胖患者(BMI ≥ 35 kg/m2)基于总体重(TBW)或去脂体重(LBW)计算甲苯磺酸瑞马唑仑诱导剂量达到MOAA/S评分为0的差异,并纳入20名正常体重受试者作为对照(按TBW计算),所有组诱导输注速率均为12 mg/kg/h。

要点

  • 拟比较肥胖患者按TBW与LBW计算甲苯磺酸瑞马唑仑诱导剂量达到MOAA/S 0分的需求差异。
  • 纳入BMI ≥ 35 kg/m2的肥胖受试者,另设20名正常体重对照(18.5 ≤ BMI < 25 kg/m2)按TBW计算。
  • 所有组诱导期甲苯磺酸瑞马唑仑输注速率均为12 mg/kg/h。

核心结论

  • 研究结果将为甲苯磺酸瑞马唑仑剂量标量提供证据,以指导肥胖患者麻醉诱导的临床实践。

研究设计与样本

  • 前瞻性、单中心、双盲、对照临床试验。
  • 比较肥胖受试者(BMI ≥ 35 kg/m2)基于总体重(TBW)或去脂体重(LBW)计算甲苯磺酸瑞马唑仑达到MOAA/S评分为0的剂量需求。
  • 另纳入20名正常体重受试者(18.5 kg/m2 ≤ BMI < 25 kg/m2)作为对照组,其诱导剂量按TBW计算。

关键数值与推荐

  • 所有组甲苯磺酸瑞马唑仑诱导期输注速率均为12 mg/kg/h。
  • 肥胖受试者BMI ≥ 35 kg/m2;正常体重对照18.5 kg/m2 ≤ BMI < 25 kg/m2。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The physiologic and anthropometric characteristics changes associated with obesity may result in the alternation of pharmacologic management. Remimazolam tosylate is a new type of ultra-short-acting benzodiazepine with stable context-sensitive half-time (CSHT) and no lipid accumulation after long-time infusion. Although remimazolam tosylate has potential advantages for the induction and maintenance of anesthesia in obese patients, the appropriate induction dosing scalars among obese patients are unknown. Therefore, we aim to compare the different weight-based scalars for dosing remimazolam tosylate of anesthesia induction among obese patients. METHODS/DESIGN: The study will be performed as a prospective, single-center, double-blind, controlled clinical trial. The study design is a comparison of remimazolam tosylate requirements based on total body weight (TBW) or lean body weight (LBW) to reach a Modified Observer's Assessment of Alertness and Sedation (MOAA/S) score of 0 among obese subjects (BMI ≥ 35 kg/m2). Another twenty normal-weight subjects (18.5 kg/m2 ≤ BMI < 25 kg/m2) will be enrolled as a control group, whose induction dose is scaled based on TBW. The infusion rate of remimazolam tosylate during induction is 12 mg/kg/h in all groups. DISCUSSION: Results of the present study will provide evidence of dose scalar of remimazolam tosylate to guide the clinical practice of anesthesia induction in obese patients. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR220005664. Registered on 9 February 2022, https://www.chictr.org.cn/showproj.aspx?proj=151150 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ni W, Yi X, Feng L, et al. Comparison of different weight-based scalars of remimazolam tosylate for anesthesia induction in obese patients: study protocol for a prospective, controlled trial. Trials. 2023. PMID: 37950290. doi:10.1186/s13063-023-07739-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。